Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Clinical trial NCT02506153 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02506153
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Cutaneous Melanoma Metastatic Mucosal Melanoma Metastatic Non-Cutaneous Melanoma Non-Cutaneous Melanoma Recurrent Cutaneous Melanoma Recurrent Mucosal Melanoma Recurrent Non-Cutaneous Melanoma

Start date: 2015-11-10
Primary completion: 2023-09-15
Enrollment: 1301

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.